Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gliclazide, quantity: 30 mg - tablet, modified release - excipient ingredients: hypromellose; mannitol; lactose monohydrate; sodium acetate; silicon dioxide; magnesium stearate - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gliclazide, quantity: 60 mg - tablet, modified release - excipient ingredients: mannitol; magnesium stearate; sodium acetate; silicon dioxide; hypromellose; lactose monohydrate - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gliclazide, quantity: 30 mg - tablet, modified release - excipient ingredients: hypromellose; magnesium stearate; mannitol; lactose monohydrate; silicon dioxide; sodium acetate - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gliclazide, quantity: 60 mg - tablet, modified release - excipient ingredients: silicon dioxide; mannitol; lactose monohydrate; magnesium stearate; sodium acetate; hypromellose - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gliclazide, quantity: 30 mg - tablet, modified release - excipient ingredients: hypromellose; magnesium stearate; silicon dioxide; sodium acetate; mannitol; lactose monohydrate - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

Philippines - English - FDA (Food And Drug Administration)

zoetis philippines, inc. - modified live pseudorabies virus vaccine - lyophilized powder for injection (im) - formulation: each 2 ml of reconstituted vaccine contains: modified live pseudorabies virus vaccine (bucharest strain) * tcid, 50% endpoint 1045tcid50*

Philippines - English - FDA (Food And Drug Administration)

msd animal health (phils), inc.; distributor: msd animal health (phils), inc. - modified live canine distemper virus (cdv) , canine adenovirus type 2 (cav-2) , canine parainfluenza virus (cpi) , canine parvovirus (cpv) , inactivated leptospira interrogans ser. canicola , leptospira interrogans ser. icterohaemorrhagiae , coronavirus vaccine (vet.) - suspension for injection (im/sc) - formulation: each dose of dappvla vaccine contains: modified live virus canine distemper virus (cdv) (distemperoid strain) >10^3.7 tcid 50/dose modified live virus canine adenovirus type 2 (cav-2) (ditchfield strain) >10^4.8 tcid 50/dose modified live virus canine parainfluenza (cpi) (cpi-pr strain)- >10^4.3 tcid 50/dose modified live virus canine parvovirus (cpv) (sah-cpv-2b strain) >10^5.1 tcid 50/dose bacterin leptospira canicola (lc-ny strain)>80 hamster pd80 bacterin leptospira icterohaemorrhagiae (li-11403 j strain)>80 hamster pd80 each dose of canine 1-cv vaccine contains: killed virus feline enteric coronavirus (fecv) (wsu 79-1683(3) strain) >1 rp/dose tcid-test culture infectious dose faid- flouroscent antibody infect due pd-protective dose rp-relative potency

Ireland - English - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - gliclazide - modified-release tablet - 60 milligram(s) - sulfonamides, urea derivatives; gliclazide

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - misoprostol; diclofenac sodium - modified-release tablet - 50 mg/0.2 milligram(s) - acetic acid derivatives and related substances; diclofenac, combinations

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - diclofenac sodium; lactose monohydrate; misoprostol - modified-release tablet - 75/0.2 milligram(s) - acetic acid derivatives and related substances; diclofenac, combinations